Infectious Diseases - Summary
Table of all ID conditions organised by history findings, examination findings, investigation findings and management according to Australian guidelines.
Viral Infections
Info History/RF Examination Investigation Management
HIV/AIDS Ax – Stages – Bedside – BSL, pharyngeal Ongoing disease – HAART
HIV – human Transmission – serous fluids, sexual, Primary infection – acute retroviral syndrome swab, sputum testing (Highly active anti-
immunodeficiency paraenteral, needles, vertical retroviral therapy)
virus Stage 1 – slow decline in CD4 count; viral set point after Bloods – Will reduce viral load,
HIV 1 – Global 3mo; latent stage (no Sx); lasts 1-15 yrs; may have FBE, CRP, ESR, UEC, LFT increase CD4 count, reduce
pandemic/US, Epi – 1.7 million people infected in 2018, generalized lymphadenopathy Serum CD4 count – staging transmission, improve QoL
more common AID develops 10-15 yrs after HIV infection Stage 2 – slow declined in CD4 count, slight immune and progression of the Triple therapy – combo of
HIV 2 – restricted suppression; some more frequent infections – mouth disease anti-retroviral therapy –
to West Africa ulcers, recurring URTI, influenza, dermatitis; around 2 yrs Viral RNA load – infectious a NRTIs, NNRTIs, protease
Prevention – usually person is inhibitors
AIDS – acquired Screening blood products Stage 3 – CD4 count in 300s; constitutional Sx – Can get viral load to 0 – no
immune deficiency Safe needle usage infections, LOW, fever, diarrhoea, oral infections, deVere Imaging – longer transmissible
syndrome Barrier protection – condoms bacterial infections, dental issues, anaemia, around 2 yrs CXR
End stage of HIV RF prevention Stage 4 - <200 CD4 count +/- presence of AIDS defining Specialist referral
Defined by a series illnesses Dx Test Need thorough regular
of infections and Pre-exposure prophylaxis (PREP) HIV wasting syndrome – LOW >10% + chronic diarrhoea Rapid HIV test – screening follow up
malignancies = Give to high risk of being exposed – or fever >1 mo test (within first 3 weeks of Social and peer support
AIDS defining partners of someone with HIV, sex Pneumocystis jirovecii pneumonia (PJP) exposure, if ELISA not
illnesses worker, IVDU, no barrier protection >2 severe LRTI per year possible,, confirm w/ ELISA at Acute exposure – note the
CD4 T cell count Daily anti-virals – tenofovir and Oesophageal candidiasis 3mo) details of the person they
<200micrometres/L emtricitabine Secondary or military TB ELISA test – identify presence received it from – stage,
ADR – N/V, diarrhoea, headache Kaposi’s sarcoma of antibody; false -ive within CD4, viral load
CMV 3mo of infection, antibodies
Cryptococcal infections have not developed yet; PEP – Post exposure
Pathophys – HIV targets CD4 cells
HIV encephalopathy ALWAYS repeated at 3mo prophylaxis
(macrophages, dendritic cells, Th cells)
Cryptosporidium Serum western blot – best, Given to definite exposure
Non-Hodgkin lymphoma but $$$ to someone with
Invasive cervical Ca confirmed HIV
Within 72 hrs begin; 28 day
RF – IVDU, MWHSWM, sexual Hx – girls, guys, both, course of 3 anti-retrovirals
vaginal, oral, anal, insertive, receptive, barrier protection ADR – gut issues
EBV Ax – EBV (knowns as HHV-4); Generalised Lymphadenopathy – Bedside – Conservative
transmission – highly contagious and fatigue/malaise mobile, usually posterior Throat swab – rule out strep Fluid
Primary infection – spreads via bodily secretions, esp saliva cervical throat Rest
asymptomatic Pathophys – Tonsilitis or pharyngitis, Splenomegaly Analgesia – Panadol &
Symptomatic EBV infects B cells and epithelial cells in exudative pharyngitis, Hepatomegaly Bloods – nurofen
infection – tonsils → primary infection severe, for 3-5 days Leukoplakia – white FBE – presence of 50%
infectious (asymptomatic) Fever – mild, lasting 2 patches or spots (lesions) lymphocytes with at least Avoid contact sport – risk
mononucleosis Incubation period 2-6 weeks – EBV weeks form inside the mouth 10% atypical lymphocytes of splenic rupture
(AKA glandular replicates in B cells → virus shed into Other – headache, abdo (resemble monocytes) Avoid amoxycillin – itchy
, fever) saliva pain, N/V LFTs macropapular rash in up to
EBV induces immune response → B cells IgG, IgM, EBV antibody titre 90% of people
mounts immune response locally (tonsils) Serology
or in other places (lymph nodes, spleen, Blood film – possible red cell
liver)- symptomatic agglutination
B cells stimulate CD8 T cell activity; B cells
also activated → plasma cells → Special tests
produced antibodies against EBV Monospot – rapid, specific,
B cells stimulate CD8 T cell activity; B cells but not sensitive; presence of
also activated → plasma cells → heterophile antibodies
produced antibodies against EBV produced by infected B cells
Cx – splenomegaly (splenic rupture),
hepatomegaly (hepatitis), rash due to
amoxycillin, post-infective chronic fatigue
syndrome, encephalitis, B-, T and NK-cell
derived Ca e.g Burkitt’s lymphoma,
airway compromise due to large tonsils
Influenza Ax – class of orthomoxyvirus (spherical Viral URTI – headache, myalgia, fever, sweats, rigors, Nasopharyngeal swab + PCR Symptomatic – rest,
Characterised by RNA virus); Influenza A – large pandemics sore throat, cough, nasal congestion Serology hydration, analgesia
upper and lower due to antigenic shift/drift; influenza B – Sick contacts High risk – can give anti-
respiratory tract Sx smaller outbreaks i.e epidemics due to Vaccinations Clinical Dx virals – oseltamivir
Usually in winter antigenic drift i.e point mutations in H Smoking Start within 48 hrs of Sx,
season and N enzymes; Influenza C – rare variant Underlying resp pathology – CF, bronchiectasis, reduces Sx by 1-2 days
Transmission – directly via respiratory immunosuppression – corticosteroids, chemo
droplets (sneezing or coughing) or Recent travel Prevention – hygiene,
indirectly through contact with seasonal vaccination – esp
contaminated surfaces if at high-risk e.g young
kids, elderly, comorbid
Incubation period – 2-3 days illnesses
Oseltamivir can be used
prophylactically for high
risk
Stay at home if sick
Dengue Ax – dengue virus (serotype – DENV 1-4); High fever Bedside – Assess severity and
Viral disease RNA virus of the genus flavivirus Headache Bloods – therefore admission
transmitted by Transmission – vector-borne – Body aches – arthralgia, myalgia FBE – Hct elevated, Fluid resus (+/- blood
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller nikitagoyal. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $7.79. You're not tied to anything after your purchase.
